83 results about "Autistic disorders" patented technology

The present invention relates to methods and compositions for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone. Distress Dysfunction refers to the experience of dysfunctional emotional and physical distress that interferes with the individual's quality of life and functioning. A novel understanding of the bimodal opioid modulation of pain, and its impact, through serotonergic, dopaminergic, epinephrinergic, and norepinephrinergic processes, on hedonic tone, leads directly to new generation pharmaceutical formulations that are remarkably safe and effective for the treatment of a wide variety of Distress Dysfunctions, including anxiety, depression, anger, insomnia, mood disorders, eating disorders, sexual problems, pain, substance and behavioral addictions, gastrointestinal disorders, autistic spectrum disorders, attention-deficit and hyperactivity disorders, and other emotional and physical distress disorders. The foundation of this discovery is the power of Receptor Switchers, such as ultra-low-dose and very-low-dose opioid antagonists and GM1 ganglioside attenuators, in blocking acute and protracted excitatory opioid receptor signaling. Co-administration of Receptor Switchers with Endorphin Enhancers, such as specific cAMP PDE inhibitors and excitatory amino acids, is an excellent formulation for restoring healthy homeostatic balance to the endogenous opioid system, using the body's endorphins to reduce emotional and physical distress, and through synergistic and homeostatic processes, restoring positive hedonic tone. The addition of Synergistic Enhancers, such as amino acids, SSRI and SNRI agents, and non-opioid analgesics, as well as Exogenous Opioids, enhances and prolongs these therapeutic benefits. The novel principles discovered by this invention also teach a new generation of safe and effective formulations for the treatment of respiratory conditions, neuropathy, and nociceptive pain.

Methods of treating or suppressing Pervasive Developmental Disorders (PDDs) including; Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder (CDD), Rett's Disorder, and PDD-Not Otherwise Specified (PDD-NOS) comprising administering to a subject in need thereof a therapeutically effective amount of a tocotrienol, a tocotrienol ester, a tocotrienol ether, a tocotrienol enriched extract or mixtures thereof.

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit / hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit / hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

The present invention provides heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein.The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention provides arylpiperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression.

The present invention provides novel quinolinone derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.

The present invention relates to a method for preparing autistic model dogs by gene editing techniques, obtained autistic model dogs, and cells and tissues of the autistic model dogs. The method comprises the steps of: (1) acquiring Shank3 knockout type autistic model canine fertilized eggs by using a gene editing technique; and (2) transplanting the Shank3 knockout type autistic model canine fertilized eggs to one fallopian tube of a female dog subjected to egg flushing on bilateral fallopian tubes, thereby preparing the Shank3 knockout type autistic model dogs.

Disclosed are compositions and methods for the treatment of a subject having an autism spectrum disorder. The disclosed compositions may contain racemic ketamine or S-ketamine. The disclosed methods of administering the compositions include intranasal administration to a subject having an autism spectrum disorder.

The present invention provides novel piperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression.

The present invention is a method for the treatment of Pervasive Developmental Disorders (PDDs) including; Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder (CDD), Rett's Disorder, and PDD-Not Otherwise Specified (PDD-NOS) comprising administering to a subject in need thereof a therapeutically effective amount of one or more carbamate compounds of Formula 1 and / or Formula 2 as herein defined and shown below.The present invention is directed to a method for the treatment of Pervasive Developmental Disorders (PDDs) including; Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder (CDD), Rett's Disorder, and PDD-Not Otherwise Specified (PDD-NOS), which includes mono-therapy and alternatively, co-therapy with at least one additional psychoactive medication.

The present invention provides arylpiperazine derivatives having Formula I which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression.

A medical garment system for comfortably restraining at least one limb of a gown wearer while permitting the wearer to receive medical treatment. The medical garment system is particularly useful for special needs patients, such as autistic children, who may become frightened when medical personnel are attempting to administer medication. Such patients may react by violently moving their arms, causing themselves or the medical personnel harm. When the arms of such a patient are comfortably subdued during such procedures, the patient is better protected from injury.

This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.

The invention belongs to the field of automatic control and robots and relates to a three-wheeled omnidirectional mobile control device. The device adopts double front wheels for drive to improve the driving capacity and bearing capacity of robots. With V_Rotation rotation factor introduced and incremental PID controlling the whole adjusting process, the device realizes the accurate linear and arc movement of robots in any direction, as well as automatic avoidance of barrier and path planning. The robot device and the control technology aim at real-time custody and auxiliary treatment of autistic children. The invention provides a technology of emotion capture and emotion interaction of interactive objects by robots during man-machine interaction process, so as to improve the affinity and interactive success rate of robots in man-machine interaction.

This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder—Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.

The invention discloses a space perception ability training device for autistic children. The device organically combines auditory sense, visual sense and tactile sense, and related plastic nerves inthe brain and a repair path of brain self-healing ability are perceived through stimulation of multiple sense organs. Moreover, the device performs hierarchical mode training on the ability of the autistic children from distinguishing spatial positioning, understanding spatial orientation concepts to analyzing spatial relations, and achieves coordinated movement of hands, feet, eyes and brains, thereby improving the integration function and the spatial perception ability of the autistic children. The scientific, normalized, professional, systematic and standardized spatial perception ability training device and method are provided for the autistic children and rehabilitation guidance personnel, the accuracy of training results is effectively guaranteed, and the workload of teachers or guardians is greatly reduced.

An aminomethylpyridyloxymethyl / benzisoxazole substituted azabicyclic compound, a pharmaceutical composition comprising same, and a method of treating a cognitive disorder selected from the group consisting of Asperger's disorder, Autistic Disorder, Oppositional Defiant Disorder, and Conduct Disorder.

The invention relates to bifidobacterium longum subspecies CCFM687, fermented food and application thereof. Bifidobacterium longum infantile subspecies CCFM687 of the present invention can improve the depression-like behavior of depressed mice, improve the levels of 5-hydroxytryptamine, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice; improve depression Butyric acid content in the gut of mice; lower intestinal abundance of Desulfovibrio spp., increased abundance of Bifidobacterium and S24‑7 families, increased gut microbiota α‑diversity, and improved intestinal Intestinal flora disorder, reduce the occurrence of autism, inflammatory bowel disease, obesity and type I diabetes; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the 5-hydroxychromatin level of the cells The secretion of amino acid provides precursor substances for the synthesis of 5-hydroxytryptamine in the brain. Therefore, it has broad application value.

The present invention provides novel quinolinone derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.

An active, specialized stylus and sharp color graphics may be combined with a tactile display in order to increase accessibility to the blind and visually impaired. A tactile display may consist of an array of pins that may be raised to varying heights to represent contours and outlines of images that are recognizable when touched. A specialized stylus may allow the user to instantly create, touch and save tactile drawings or alter with multi-sensory feedback.A tactile and visual display may consist of an array of pins, with circular or squared-off tops. Physical attributes may be given to individual pins, the screen itself (LED), or a LCD WXGA or other type of projector may be incorporated so that enhanced visual imaging is combined with tactile graphics to give those with different levels of visual impairment a multisensory feedback when experiencing images or drawings. Also this technology may be used with autistic students and those with learning disabilities, as well as serve as a means of entertainment.

The invention relates to a pronunciation rehabilitation training system which comprises a machine body and a display unit located above the machine body, wherein the display unit is connected with themachine body through a lifting mechanism; the lifting mechanism comprises a lifting driving motor, a lifting push rod, a lifting sliding rail and a supporting back plate; the display unit comprises acasing, a first capacitive touch display screen, a second capacitive touch display screen and a control board. According to the pronunciation rehabilitation training system, the capacitive touch display screens are used to select a training module and display images for training demonstration, so that an autistic child can make a pronunciation by watching the images; voices of the autistic childare collected through a wireless microphone receiver, and the collected voices are transmitted to the control board; the control board determines whether the voices are matched with the images displayed on the first capacitive touch display screen and displays a judgment result through the first capacitive touch display screen so as to help a therapist to scientifically determine the pronunciationrehabilitation of the autistic child; the pronunciation rehabilitation training efficiency for the autistic child is improved.

The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the MARK1 gene on chromosome 1 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the MARKI gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and / or treatment of Asperger syndrome, pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia.

The invention provides a method of producing human immature dental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lacking expression of CD146. The invention also provides compositions for usein the treatment of a neurological disease or condition selected from the group consisting of Parkinson's disease (PD), multiple sclerosis, 5 amyotrophic lateral sclerosis (ALS), stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease, Huntington's disease (HD), autism, schizophrenia, stroke, ischemia, a motor disorder, and a convulsive disorder.

The present invention relates to trans-N-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-N′,N′-dimethylurea (cariprazine), its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations for use in the treatment of symptoms of autism spectrum disorder in general, and preferably the object of the present invention is to treat one or more symptoms of autism.Furthermore, it was also found that cariprazine, its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations are suitable for treatment of conditions such as Asperger's syndrome, atypical autism (otherwise known as pervasive developmental disorder not otherwise specified; PDD-NOS), Rett syndrome, childhood disintegrative disorder, attention deficit hyperactivity disorder (ADHD) and sensory integration dysfunction.

Disclosed herein are treatments for diseases such as sleep apnea, hyperuricemia, autistic spectrum disorder (ASD) and other brain disorders using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.

The invention discloses a virtual immersion type autistic child treatment system based on electroencephalogram signals and an eye tracker. The virtual immersion type autistic child treatment system comprises an artificial intelligence voice interaction module, an electroencephalogram detection module, an eye movement detection module, a machine learning recognition module and a virtual reality module; the electroencephalogram detection module is used for detecting electroencephalogram signals and performing feature extraction; the eye movement detection module is used for sampling eye movement data, constructing eye sight lines and performing three-dimensional visualization on eye movement fixation point data and individual movement track data; the machine learning recognition module performs pattern recognition on the data acquired by the electroencephalogram detection module and the eye movement detection module through a pre-trained machine learning model, and feeds back a recognition result; and the virtual reality module is used for building a 3D scene, reading an instruction of a feedback signal and adjusting and controlling the virtual reality scene. The system is combined with VR eye movement detection equipment, so that the reason of the emotion change of a patient can be known, and the purpose of treating the patient in a targeted manner is achieved.

The invention relates to the technical field of medical rehabilitation equipment, and particularly discloses a language training device for autistic children based on artificial intelligence. The device comprises a robot body and a movable base, the robot body comprises a lower body section, an upper body section, a robot head and robot arms, the lower body section, the upper body section and the robot head are sequentially connected from bottom to top, and the two robot arms are arranged on the two sides of the upper body section in a mirror symmetry mode. The language training device for the autistic children based on the artificial intelligence can prevent the autistic children from making contact with obstacles in the driving process, and is novel in structural design; and meanwhile, the device has a good interest cultivation function while performing language training on the autistic children, has a good treatment effect on language training of the autistic children, and is diversified in function, high in intelligent degree and excellent in use effect.